Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
4.85 USD -6.37% Intraday chart for Monte Rosa Therapeutics, Inc. -14.16% -14.16%
05-09 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-02 Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 949.7 368.3 282.8 260.6 - -
Enterprise Value (EV) 1 603.6 105.5 50.43 139 89.23 -43.84
P/E ratio -6.9 x -3.31 x -2.15 x -2.13 x -2.2 x -2.84 x
Yield - - - - - -
Capitalization / Revenue - - - 39.8 x 42.4 x 10.5 x
EV / Revenue - - - 21.2 x 14.5 x -1.77 x
EV / EBITDA -8.53 x -0.97 x -0.37 x -0.97 x -0.5 x 0.23 x
EV / FCF -8.74 x -1 x -0.8 x -1.07 x -0.63 x 0.27 x
FCF Yield -11.4% -99.9% -125% -93.5% -160% 376%
Price to Book 2.75 x 1.32 x 1.58 x 5.24 x 5.08 x 2.85 x
Nbr of stocks (in thousands) 46,506 48,399 50,062 50,311 - -
Reference price 2 20.42 7.610 5.650 5.180 5.180 5.180
Announcement Date 29/03/22 16/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - 6.554 6.154 24.83
EBITDA 1 - -70.75 -108.6 -137.1 -142.8 -178.8 -190
EBIT 1 - -72.88 -112.4 -143.3 -148.8 -173.9 -194.3
Operating Margin - - - - -2,270.63% -2,826.04% -782.53%
Earnings before Tax (EBT) 1 - -73.96 -108.5 -135 -146.9 -176 -196.5
Net income 1 -35.88 -73.96 -108.5 -135.4 -140.7 -171.7 -193.2
Net margin - - - - -2,147.49% -2,790.91% -778.03%
EPS 2 -6.700 -2.960 -2.300 -2.630 -2.432 -2.350 -1.825
Free Cash Flow 1 - -69.1 -105.4 -62.84 -130 -142.4 -164.8
FCF margin - - - - -1,983.64% -2,314.09% -663.95%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 04/06/21 29/03/22 16/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - 1.064 1.467 1.467 1.467 4.4
EBITDA - - - - - -31.42 - - - - - - - - -
EBIT 1 -19.87 -23.39 -24.3 -27.23 -28.36 -32.49 -34.26 -37.22 -36.97 -34.86 -36.01 -36.95 -39 -37.33 -44.16
Operating Margin - - - - - - - - - - -3,384.49% -2,519.4% -2,658.94% -2,544.93% -1,003.68%
Earnings before Tax (EBT) 1 -19.84 -23.4 -23.93 -26.47 -27.32 -30.78 -32.04 -34.99 -34.71 -33.27 -31.88 -35.53 -38.48 -36.04 -44.09
Net income 1 -19.84 -23.4 -23.93 -26.47 -27.32 -30.78 -32.04 -35.18 -34.88 -33.25 -31.97 -35.53 -38.48 -36.72 -44.09
Net margin - - - - - - - - - - -3,004.51% -2,422.61% -2,623.95% -2,503.66% -1,001.99%
EPS 2 -0.4300 -0.1100 -0.5100 -0.5700 -0.5800 -0.6300 -0.6500 -0.7100 -0.7000 -0.5800 -0.5300 -0.5746 -0.6169 -0.5168 -0.5950
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/11/21 29/03/22 11/05/22 11/08/22 10/11/22 16/03/23 11/05/23 10/08/23 09/11/23 14/03/24 09/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 346 263 232 122 171 304
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -69.1 -105 -62.8 -130 -142 -165
ROE (net income / shareholders' equity) - -49.5% -35.1% -60.1% -60.9% -135% -75.5%
ROA (Net income/ Total Assets) - -35.6% -30.6% -41.9% -42% -33.6% -29.1%
Assets 1 - 207.9 354.4 323.1 335.2 511 663.1
Book Value Per Share 2 - 7.430 5.750 3.570 0.9900 1.020 1.820
Cash Flow per Share - - -1.960 - - - -
Capex 1 - 9.73 12.9 19 7.35 7.23 7.53
Capex / Sales - - - - 112.17% 117.5% 30.33%
Announcement Date 04/06/21 29/03/22 16/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.18 USD
Average target price
15.43 USD
Spread / Average Target
+197.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MONTE ROSA THERAPEUTICS, INC. Stock Monte Rosa Therapeutics, Inc.
-14.16% 261M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 47.02B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 41.76B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 28.8B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.05B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.15B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.55B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.82B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. Financials Monte Rosa Therapeutics, Inc.